scPharmaceuticals
115 articles about scPharmaceuticals
-
scPharmaceuticals to Participate in the Cowen 43rd Annual Health Care Conference
2/23/2023
scPharmaceuticals Inc. today announced that John Tucker, President & Chief Executive Officer, is scheduled to participate in a fireside chat at the Cowen 43rd Annual Health Care Conference, on Wednesday, March 8 at 10:30 am ET in Boston.
-
scPharmaceuticals Announces Launch and Commercial Availability of FUROSCIX® (furosemide injection)
2/21/2023
scPharmaceuticals Inc. today announced the launch and commercial availability of FUROSCIX ® , a proprietary formulation of furosemide delivered via an on-body infusor for the outpatient treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.
-
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 06, 2023
2/6/2023
scPharmaceuticals Inc. announced that on February 1, 2023, the Compensation Committee of scPharmaceuticals’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 142,500 shares of its common stock to 38 new employees.
-
scPharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
1/31/2023
scPharmaceuticals Inc. announced that John Tucker, President & Chief Executive Officer, is scheduled to present virtually at the SVB Securities Global Biopharma Conference, on Thursday, February 16 at 11:20 am ET.
-
scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial UpdateCommercial launch planned for February 20, 2023
1/30/2023
scPharmaceuticals Inc. (Nasdaq: SCPH), today announced that the company is targeting February 20, 2023 as the date for commercial availability of FUROSCIX® (furosemide injection), a proprietary formulation of furosemide delivered via an On-Body Infusor for outpatient treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.
-
scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer
12/19/2022
scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, announced the appointment of Rachael Nokes as Chief Financial Officer.
-
scPharmaceuticals to Participate in the 12th Annual LifeSci Partners Corporate Access Event
12/14/2022
scPharmaceuticals Inc. announced that John Tucker, President & Chief Executive Officer, is scheduled to participate in the 12th Annual LifeSci Partners Corporate Access Event, on Monday, January 9 and Tuesday, January 10, 2023, in San Francisco.
-
scPharmaceuticals Announces Pricing of $50 Million Public Offering
11/22/2022
scPharmaceuticals Inc. today announced the pricing of an underwritten public offering of 6,620,000 shares of its common stock at a public offering price of $5.25 per share.
-
scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock - November 21, 2022
11/21/2022
scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, announced a proposed underwritten public offering of shares of its common stock.
-
scPharmaceuticals Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
11/9/2022
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.
-
scPharmaceuticals to Participate in the Jefferies 2022 London Healthcare Conference
11/2/2022
scPharmaceuticals Inc. announced that John Tucker, President & Chief Executive Officer, is scheduled to present at the Jefferies London Healthcare Conference, on Wednesday, November 16 at 5:35 pm GMT.
-
scPharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022
10/26/2022
scPharmaceuticals Inc. (Nasdaq: SCPH) today announced that scPharmaceuticals’ management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 9, 2022, to discuss third quarter financial results and provide a business update.
-
FDA Review: Phanes, Pfizer, GSK and More
10/14/2022
The FDA has numerous activities and interactions with Phanes, Prestige Biopharma, Reata, Pfizer and more, providing clearance, approving clinical trials and other regulatory actions. -
This week, financing came in the form of loans, private placements and a Series B, throwing support behind an injectable heart failure drug, oral immunology therapies and an ASD treatment.
-
UPDATE - scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure
10/10/2022
scPharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved FUROSCIX® (furosemide injection), a proprietary formulation of furosemide delivered via an On-Body Infusor for the treatment of congestion due to fluid overload in adults with New York Heart Association Class II/III chronic heart failure.
-
scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure
10/10/2022
scPharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved FUROSCIX® (furosemide injection), a proprietary formulation of furosemide delivered via an On-Body Infusor for the treatment of congestion due to fluid overload in adults with New York Heart Association Class II/III chronic heart failure.
-
scPharmaceuticals Announces $100 Million Debt Financing Agreement with Oaktree
10/10/2022
scPharmaceuticals Inc. today announced that the company has entered into a binding term sheet with respect to a $100 million secured debt facility with funds managed by Oaktree Capital Management, L.P. (“Oaktree”).
-
Theratechnologies’ Trogarzo for HIV, Alnylam’s Lumasiran for advanced primary hyperoxaluria, scPharmaceuticals' Furoscix for heart failure and more. Here's a look at the FDA's October calendar.
-
scPharmaceuticals Announces Data Presentations at the Heart Failure Society of America 2022 Annual Scientific Meeting
9/30/2022
scPharmaceuticals Inc. today announced two poster presentations, including a late breaker, at the Heart Failure Society of America (HFSA) 2022 Annual Meeting, which is being held September 30 – October 3, in Washington DC.
-
scPharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
9/1/2022
scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, announced today that John Tucker, president & chief executive officer, is scheduled to present virtually at the H.C. Wainwright 24th Annual Global Investment Conference.